<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Children living in <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e>-endemic regions have a high incidence of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), the etiology of which involves <z:e sem="disease" ids="C0024535" disease_type="Disease or Syndrome" abbrv="">Plasmodium falciparum malaria</z:e> and Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we compared EBV DNA loads in plasma and saliva samples from Ugandan children with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> (M+) at the time of diagnosis and 14 days after antimalaria treatment, children without <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> (M-), and children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>EBV DNA was detected, by real-time polymerase chain reaction, in 31% of the plasma and in 79% of the saliva samples from children in the M+ group </plain></SENT>
<SENT sid="3" pm="."><plain>Antimalaria treatment led to clearance of plasma <z:mp ids='MP_0001799'>viral</z:mp> load in 85% of the cases but did not affect the levels in saliva </plain></SENT>
<SENT sid="4" pm="."><plain>There was a significant difference in plasma EBV loads across the groups </plain></SENT>
<SENT sid="5" pm="."><plain>The lowest levels were detected in samples from the M- group, increased levels were detected in samples from the M+ group, and levels reached the highest values in samples from children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The same trend was evident in the frequency and levels of anti-BZLF1 antibodies, which is indicative of <z:mp ids='MP_0001799'>viral</z:mp> reactivation </plain></SENT>
<SENT sid="7" pm="."><plain>In the M+ group, the positive plasma samples clustered around 7-9 years of age, the peak incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The clearance of circulating EBV after antimalaria treatment suggests a direct relationship between active <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:mp ids='MP_0001799'>viral</z:mp> reactivation </plain></SENT>
</text></document>